Life science laboratories saw a massive drop in demand last year after the NIH was forced to cancel billions of dollars in research grants.
Get this delivered to your inbox, and more info about our products and services.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
RBC analyst Conor McNamara told CNBC the wait might be a little longer.
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.
A failed acquisition bid, U.S. pricing deals, and boardroom drama pose challenges for the Danish pharma giant.
The investment bank upgraded the pharma stock to overweight from equal weight.
